These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4411256)

  • 1. [Therapy of arterial occlusive diseases with Dusodril].
    Fortschr Med; 1974 Jul; 92(20):873-4. PubMed ID: 4411256
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical experiences with naftidrofuryl in peripheral arterial occlusive diseases].
    Hauch E; Lévai Z
    Med Welt; 1973 Oct; 24(43):1665-6. PubMed ID: 4764064
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changes of lower leg blood circulation during oral therapy with naftidrofuryl (dusodril)].
    Kriessmann A; Rädler M
    Munch Med Wochenschr; 1973 Mar; 115(12):508-10. PubMed ID: 4739661
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vasodilator agents in peripheral arterial occlusive disease with coronary insufficiency, myocardial infarct and pacemakers. Electrocardiographic studies in intravenous naftidrofuryl-infusion].
    Heidrich H; Wehselau H
    Med Welt; 1974 Jul; 25(26):1161-3. PubMed ID: 4845152
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effectiveness of Dusodril-Pi in arterial occlusive diseases. A multicentric double-blind study].
    Becker HM; Elert O; Häring R; Maurer PC; Raithel D; Sperling M; Stockmann U; Storz LW; Hirche H
    Med Welt; 1979 Oct; 30(43):1602-6. PubMed ID: 514039
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of functional changes in arteriosclerotic chronic obliterating peripheral arterial diseases (COPA) and Buerger's and Raynaud's diseases with pharmacological sympathicolysis, with or without indirect surgical treatment].
    Bagliani A; Borri P; Taborelli R
    Minerva Cardioangiol; 1973 Jun; 21(6):439-52. PubMed ID: 4720185
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of primary and secondary Raynaud's syndrome using naftidrofuryl (Dusodril)].
    Kriessmann A; Sauer E
    Dtsch Med J; 1971 Dec; 22(23):743-5. PubMed ID: 5135008
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical experience with the new vasoactivator Dusodril. Results of clinical tests and a double-blind experiment].
    Bötticher R; Raithel D
    Med Klin; 1971 Nov; 66(46):1571-3. PubMed ID: 4944892
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic results in peripheral and cerebrovascular blood circulation disorders following the administration of Dusodril].
    Kaufmann J; Förster W
    Z Allgemeinmed; 1970 May; 46(13):688-9. PubMed ID: 5522940
    [No Abstract]   [Full Text] [Related]  

  • 10. [Naftidrofuryl, a new blood vessel-active substance in the preparation for arterial vascular surgery].
    Becker HM
    Med Klin; 1970 Feb; 65(8):359-61. PubMed ID: 5519232
    [No Abstract]   [Full Text] [Related]  

  • 11. [Functional results of oral dusodril therapy of obliterating arteriopathy of the lower extremities. Comparison of the angiogram, plethysmogram and Doppler ultrasound].
    Weidinger P
    Med Welt; 1983 Apr; 34(17):531-4. PubMed ID: 6865725
    [No Abstract]   [Full Text] [Related]  

  • 12. [Naftidrofuryl in venous pathology].
    Milleret PG
    Phlebologie; 1970; 23(2):189-91. PubMed ID: 5448640
    [No Abstract]   [Full Text] [Related]  

  • 13. [Angiodilatator therapy in otology: value of Praxilene].
    Bordes LR; Baradat P; Lienhart H; Debrie JC
    Rev Laryngol Otol Rhinol (Bord); 1971; 92(11):858-63. PubMed ID: 5151167
    [No Abstract]   [Full Text] [Related]  

  • 14. [Naftidrofuryl in the treatment of obstructive arterial diseases of the lower extremities].
    Ciammaichella A; Solitro A; Arcuri P
    Minerva Cardioangiol; 1975 Oct; 23(10):607-21. PubMed ID: 1232566
    [No Abstract]   [Full Text] [Related]  

  • 15. [Naphthydrofuryl in neurology].
    Ahumada BH
    Prensa Med Argent; 1971 Jul; 58(21):1067-70. PubMed ID: 5096690
    [No Abstract]   [Full Text] [Related]  

  • 16. [Value of vasodilator agents in neuropsychiatric practice and study of the indications for Praxilene].
    Bornstein S; Sère de Rivières H
    Therapeutique; 1972 Jan; 48(1):27-34. PubMed ID: 5046366
    [No Abstract]   [Full Text] [Related]  

  • 17. [Naftidrofuryl in stages III and IV of peripheral arterial occlusive disease].
    Horsch S
    Vasa Suppl; 1988; 24():38-43. PubMed ID: 3212602
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thrombocyte function in parenteral naftidrofuryl therapy].
    Janka HU; Rinninger F; Mehnert H
    Ther Ggw; 1982 Jul; 121(7):422-33. PubMed ID: 7051401
    [No Abstract]   [Full Text] [Related]  

  • 19. [Intravenous infusion of Naftidrofuryl in the treatment of arterial diseases of the limbs. Clinical and functional study].
    Schmidt C; Royer RJ; Kissel P
    Therapie; 1974; 29(6):915-23. PubMed ID: 4618388
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison between xenon 133 and thermography in experimental study of a vasodilator agent].
    Beurey J; Weber M; Saussure M; Bertrand A; Robert J
    Bull Soc Fr Dermatol Syphiligr; 1972; 79(1):68-70. PubMed ID: 4565812
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.